Assessing Mandatory HPV Vaccination: Who Should Call the Shots?

Saslow D. , “American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and its Precursors,” CA: A Cancer Journal for Clinicians 57, no. 1 (2007): 7–28.

Editorial, “Should HPV Vaccination Be Mandatory for All Adolescents?” The Lancet 368, no. 9543 (2006): 1212.

U.S. Food and Drug Administration, FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus: Rapid Approval Marks Major Advancement in Public Health , Press Release, June 8, 2006, available at <http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html> (last visited March 5, 2008).

Centers for Disease Control and Prevention, CDC's Advisory Committee Recommends Human Papillomavirus Virus Vaccination , Press Release, June 29, 2006, available at <http://www.cdc.gov/od/oc/media/pressrel/r060629.htm> (last visited March 5, 2008).

Pollack A. Saul S. , “Lobbying for Vaccine to Be Halted,” New York Times, February 21, 2007, availiable at <http://query.nytimes.com/gst/fullpage.html?sec=health&res=9403E6D6123EF932A15751C0A9619C8B63&n=Top%2FReference%2FTimes%20Topics%2FPeople%2FS%2FSaul%2C%20Stephanie> (last visited March 14, 2008).

Centers for Disease Control and Prevention, Childcare and School Immunization Requirements, 2005–2006 , August 2006, available at <http://www.immunize.org/laws/2005–06_izrequirements.pdf> (last visited March 5, 2008).

Centers for Disease Control and Prevention, “A Closer Look at Human Papillomavirus (HPV),” 2000, available at <http://www.cdc.gov/std/Trends2000/HPV-close.htm> (last visited March 5, 2008); Centers for Disease Control and Prevention, “Genital HPV Infection — CDC Fact Sheet,” May 2004, available at <http://www.cdc.gov/std/HPV/STDFact-HPV.htm> (last visited March 5, 2008).

See Saslow , supra note 1.

Datta S. D. , “Sentinel Surveillance for Human Papillomavirus among Women in the United States, 2003–2004,” in Program and Abstracts of the 16th Biennial Meeting of the International Society for Sexually Transmitted Diseases Research, Amsterdam, The Netherlands, July 10–13, 2005.

Centers for Disease Control and Prevention, “Human Papillomavirus (HPV) Infection,” July 2, 2007, available at <http://www.cdc.gov/std/hpv/default.htm> (last visited March 5, 2008).

Nichols J. R. , “Human Papillomavirus Infection: The Role of Vaccination in Pediatric Patients,” Clinical Pharmacology and Therapeutics 81, no. 4 (2007): 607–610.

See Saslow , supra note 1.

Walboomers J. M. , “Human Papillomavirus is a Necessary Cause of Invasive Cervical Cancer Worldwide,” Journal of Pathology 189, no. 1 (1999): 12–19.

Chan J. K. Berek J. S. , “Impact of the Human Papilloma Vaccine on Cervical Cancer,” Journal of Clinical Oncology 25, no. 20 (2007): 2975–2982.

See Saslow , supra note 1.

Simma B. , “Squamous-Cell Carcinoma Arising in a NonIrradiated Child with Recurrent Respiratory Papillomatosis,” European Journal of Pediatrics 152, no. 9 (1993): 776–778.

Dunne E. F. , “Prevalence of HPV Infection among Females in the United States,” JAMA 297, no. 8 (2007): 813–819.

Markowitz L. E. , “Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” Morbidity and Mortality Weekly Report 55, no. RR-2 (2007): 1–24.

Koutsky L. A. , “A Controlled Trial of a Human Papillomavirus Type 16 Vaccine,” New England Journal of Medicine 347, no. 21 (2002): 1645–1651; Brown D. R. , “Early Assessment of the Efficacy of a Human Papillomavirus Type 16L1 Virus-Like Particle Vaccine,” Vaccine 22, nos. 21–22 (2004): 2936–2942; Wheeler C. M. , “Advances in Primary and Secondary Interventions for Cervical Cancer: Human Papillomavirus Prophylactic Vaccines and Testing,” Nature Clinical Practice Oncology 4, no. 4 (2007): 224–235; Villa L. L. , “Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Young Women: A Randomized Double-Blind Placebo-Controlled Multicentre Phase II Efficacy Trial,” The Lancet Oncology 6, no. 5 (2005): 271–278; see Saslow , supra note 1.

Id. (Villa).

See Wheeler , supra note 19.

Miller N. B. , Clinical Review of Biologics License Application for Human Papillomavirus 6, 11, 16, 18 L1 Virus Like Particle Vaccine (S. cerevisiae) (STN 125126 GARDASIL), manufactured by Merck, Inc.,” Food and Drug Administration, June 8, 2006, available at <http://www.fda.gov/cber/review/hpvmer060806r.pdf> (last visited March 5, 2008).

Centers for Disease Control and Prevention, HPV Vaccine — Questions and Answers for the Public , June 28, 2007, available at <http://www.cdc.gov/vaccines/vpd-vac/hpv/downloads/hpv-gardasil-gbs.pdf> (last visited April 2, 2008).

National Conference of State Legislatures, “HPV Vaccine,” July 11, 2007, available at <http://www.ncsl.org/programs/health/HPVvaccine.htm> (last visited March 5, 2008).

S.B. 1230, 2006 Session, Virginia (2007); H.B. 2035, 2006 Session, Virginia (2007).

HPV Vaccination and Reporting Act of 2007 , B.17–0030, 18th Council, District of Columbia (2007).

Governor of the State of Texas, Executive Order RP65, February 2, 2007, available at <http://www.governor.state.tx.us/divisions/press/exorders/rp65> (last visited March 5, 2008).

S.B. 438, 80th Legislature, Texas (2007); H.B. 1098, 80th Legislature, Texas (2007).

The states are Colorado, Maine, Nevada, New Mexico, New York, North Dakota, Rhode Island, and South Carolina. See National Conference of State Legislatures, supra note 24.

The states are Colorado, Indiana, Iowa, North Carolina, North Dakota, Texas, Utah, and Washington. Id. (National Conference of State Legislatures).

The states are Maryland, Minnesota, and New Mexico. Id. (National Conference of State Legislatures).

Centers for Disease Control and Prevention, RotaShield (Rotavirus) Vaccine and Intussusception , 2004, available at <http://www.cdc.gov/vaccines/vpd-vac/rotavirus/vacrotashield-historical.htm> (last visited March 14, 2008); Rennels M. B. , “The Rotavirus Vaccine Story: A Clinical Investigator's View,” Pediatrics 106, no. 1 (2000): 123–125.

Mao C. , “Efficacy of Human Papilomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial,” Obstetrics and Gynecology 107, no. 1 (2006): 18–27.

Villa L. L. , “Immunologic Responses Following Administration of a Vaccine Targeting Human Papillomavirus Types 6, 11, 16 and 18,” Vaccine 24, no. 27–28 (2006): 5571–5583; Harper D. M. , “Sustained Efficacy Up to 4.5 Years of a Bivalent L1 Virus-Like Particle Vaccine against Human Papillomavirus Types 16 and 18: Follow Up from a Randomized Controlled Trial,” The Lancet 367, no. 9518 (2006): 1247–1255.

Hodge J. G. Gostin L. O. , “School Vaccination Requirements: Historical, Social, and Legal Perspectives,” Kentucky Law Journal 90, no. 4 (2001–2002): 831–890.

Duffy J. , “School Vaccination: The Precursor to School Medical Inspection,” Journal of the History of Medicine and Allied Sciences 33, no. 3 (1978): 344–355.

See Hodge Gostin , supra note 36.

Jacobson v. Commonwealth of Massachusetts , 197 U.S. 11 (1905).

Gostin L. O. Hodge J. G. , “The Public Health Improvement Process in Alaska: Toward a Model Public Health Law,” Alaska Law Review 17, no. 1 (2000): 77–125.

Zucht v. King , 260 U.S. 174 (1922).

Hinman A. R. , “Childhood Immunization: Laws that Work,” Journal of Law, Medicine & Ethics 30, no. 3 (2002): 122–127; Malone K. M. Hinman A. R. , “Vaccination Mandates: The Public Health Imperative and Individual Rights,” in Goodman R. A. , Law in Public Health Practice (New York: Oxford University Press, 2006).

See Centers for Disease Control and Prevention, supra note 6.

Lo B. , “HPV Vaccine and Adolescents' Sexual Activity: It Would Be a Shame If Unresolved Ethical Dilemmas Hampered This Breakthrough,” BMJ 332, no. 7550 (2006): 1106–1107.

Zimmerman R. K. , “Ethical Analysis of HPV Vaccine Policy Options,” Vaccine 24, no. 22 (2006): 4812–4820.

Stanwyck C. , “Vaccination Coverage Among Children Entering School — United States, 2005–06 School Year,” JAMA 296, no. 21 (2006): 2544–2547.

See Hodge Gostin , supra note 36.

Calandrillo S. P. , “Vanishing Vaccinations: Why Are So Many Americans Opting Out of Vaccinating Their Children?” University of Michigan Journal of Legal Reform 37 (2004): 353–440.

Hart B. , “My Daughter Won't Get HPV Vaccine,” Chicago Sun Times, February 25, 2007, at B6.

Cummings J. , “Seventy Percent of U.S. Adults Support Use of the Human Papillomavirus (HPV) Vaccine: Majority of Parents of Girls under 18 Would Want Daughters to Receive It,” Wall Street Journal Online 5, no. 13 (2006), available at <http://www.harrisinteractive.com/news/newsletters/wsjhealthnews/WSJ0nline_HI_Health-CarePoll2006vol5_iss13.pdf> (last visited March 5, 2008).

Marbella J. , “Sense of Rush Infects Plan to Require HPV Shots,” Baltimore Sun, January 30, 2007, available at <http://www.redorbit.com/news/science/819751/the_baltimore_sun_jean_marbella_column_sense_of_rush_infects/index.html> (last visited March 14, 2008).

Reimer S. , “Readers Worry About HPV Vaccine: Doctors Say It's Safe,” Baltimore Sun, April 3, 2007.

Pollack A. Saul S. , “Lobbying for Vaccine to Be Halted,” New York Times, February 21, 2007, available at <http://query.nytimes.com/gst/fullpage.html?sec=health&res=9403E6D6123EF932A15751C0A9619C8B63&n=Top%2FReference%2FTimes%20Topics%2FPeople%2FS%2FSaul%2C%20Stephanie> (last visited March 14, 2008).

Partridge J. Koutsky L. , “Genital Human Papillomavirus in Men,” The Lancet Infectious Diseases 6, no. 1 (2006): 21–31.

See Markowitz , supra note 18.

See Partridge Koutsky , supra note 56.

Partridge J. , “Genital Human Papillomavirus Infection in Men: Incidence and Risk Factors in a Cohort of University Students,” Journal of Infectious Diseases 196, no. 15 (2007): 1128–1136. It should be noted that the higher incidence might be due to the increased sensitivity of the HPV-PCR-based testing procedure used in this recent study.

Kim J. , “Vaccine Policy Analysis Can Benefit from Natural History Studies of Human Papillomavirus in Men,” Journal of Infectious Diseases 196, no. 8 (2007): 1117–1119.

See Partridge Koutsky , supra note 56.

Barnabas R. V. Laukkanen P. Koskela P. , “Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modeling Analysis,” PLoS Medicine 3, no. 5 (2006): 624–632.

Hughess J. P. Garnett G. P. Koutsky L. , “The Theoretical Population Level Impace of a Prophylactic Human Papillomavirus Vaccine,” Epidemiology 13, no. 6 (2002): 631–639.

Elbasha D. , “Model for Assessing Human Papillomavirus Vaccination Strategies,” Emerging Infectious Diseases 13, no. 1 (January 2007): 28–41. Please note that these researchers are employed by Merck, the producer of Gardasil vaccine.

Wong Wai v. Williamson , 103 F. 1 (N.D. Cal. 1900).

Vacco v. Quill , 521 U.S. 793 (1997); Washington v. Glucksberg, 521 U.S. 702 (1997).

Pollack A. , “Rising Costs Make Doctors Balk at Giving Vaccines,” New York Times, March 24, 2007.